Our Products

Our Products

The goal of Eventide Mutual Funds is to maintain market outperformance by investing in companies that we believe excel at creating value, operate with integrity, and profit from ethical and sustainable activities. We invite individuals, advisors, and institutions to learn more about our products below, including performance, holdings, prospectus, and other details.

  • Diversified “any cap” mutual fund
  • Historically a small-mid growth emphasis
  • Tends to overweight in Healthcare sector (see Management)

Gilead Fund investment strategy

*Russell 3000, an index of the 3000 American stocks with the largest market capitalization, is created by Russell Investments and is considered to represent the stock market generally. It is not an investment product available for purchase.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

Dr. Finny Kuruvilla has a unique background in healthcare, statistics, and investing. He holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a master’s degree in Electrical Engineering and Computer Science from MIT, and a bachelor’s degree from Caltech in Chemistry. He completed his residency and fellowship at the Brigham & Women’s Hospital and Children’s Hospital Boston where he cared for adult and pediatric patients suffering from a variety of hematologic, oncologic, and autoimmune disorders. Subsequently, he was a research fellow at MIT where he designed and implemented statistical algorithms involving logistic regression and pseudo-Bayesian expectation maximization. As an avid proponent of values-based investing, Dr. Kuruvilla has developed standards for selecting ethical companies at the outset of the stock selection process.

David Barksdale has a background in software development, engineering and management and is primarily responsible for quantitative research, risk analysis and asset allocation. He holds a bachelor’s degree from Caltech in Engineering & Applied Science. By developing and applying novel analytical tools and strategies, Mr. Barksdale works to optimize portfolio returns on a risk-adjusted basis.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

As of June 30, 2016:

Eventide Gilead Fund Portfolio Composition

† Companies valued at greater than $10 billion are Large Cap; those at less than $1 billion are Small Cap. Portfolio Composition is subject to change at any time. Past performance does not assure future results.

‡ The Fund may not invest 25% or more of its total assets in a particular industry or group of industries. A sector is normally composed of many industry groups. Sector Allocation is subject to change at any time. Past performance does not assure future results.

As of June 30, 2016:

Fund Performance

Performance is historic and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. Investors cannot directly invest in an index and unmanaged index returns do not reflect any fees, expenses or sales charges. To obtain the most recent month-end performance information and a current Eventide Gilead Fund prospectus please call the fund, toll free at 1-877-771-EVEN (3836).

Eventide Gilead Fund’s Class N expenses: Total Expenses 1.43%.

† These charts compare the Eventide Gilead Fund to index fund performance over the previous periods shown, and since inception. Since Inception returns pertain to Class N and are annualized and assume the inception date of 8 July 2008. Performance will differ for other fund classes, based upon fees and commissions. Because of ongoing market volatility, Fund performance may be subject to substantial short-term changes. The S&P 500 is an index created by Standard & Poor’s of American stocks with the largest market capitalization. It is not an investment product available for purchase. The Russell Midcap Growth Index measures the performance of the U.S. equity mid-cap growth segment. It includes mid-cap companies with higher price-to-book ratios and forecasted growth. The volatility of the indices may be materially different than that of the Fund, and investors should not expect the Fund to achieve the same results as the indices listed.

‡ Returns pertain to Class N.

** Aggregate total return, not annualized.

†† Annualized since inception returns assume an inception date of 8 July 2008.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

As of June 30, 2016:

EGF-market-risk

** Source: Zephyr StyleADVISOR, with Fund returns supplied to Zephyr by Morningstar, Inc. Standard deviation of return measures the average deviations of a return series from its mean. StyleADVISOR calculates standard deviation as the square root of the squared differences of each monthly return from the mean monthly return over the specified period. Beta is a measure of systematic risk, or the sensitivity of ETGLX to movements in the the S&P 500 Index (Index). StyleADVISOR defines Beta as the covariance of ETGLX and Index divided by the variance of the Index. Alpha is the mean of the excess return of ETGLX over beta times the Index. The R-Squared (R2) of ETGLX versus the Index is a measure of how closely related the variance of ETGLX returns and the variance of the Index returns are. StyleADVISOR calculates R2 by squaring the correlation of monthly returns between ETGLX and the Index over the specified period.

†† Annualized since inception market risk details assume inception date of 1 August 2008 and not Class N’s actual inception date of 8 July 2008, as only full month data is included in the market risk calculations.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

As of June 30, 2016:

  • Celgene Corp (4.41%) Discovery, development and commercialization of life-changing cancer therapies
  • Lam Research Corp (3.97%) Supplying wafer fabrication equipment for the semiconductor industry
  • Crown Castle International Corp (3.76%) Infrastructure for broadcasting and mobile telephony
  • Lowe’s Cos Inc (3.76%) 1,800 home improvement stores in the U.S., Canada and Mexico
  • Macquarie Infrastructure Corp (3.72%) Aircraft services, liquid storage and marine terminals
  • Lear Corp (3.19%) Building seats and electrical systems for cars
  • AbbVie Inc (3.14%) Discovering, developing and making pharmaceuticals
  • XPO Logistics Inc (3.03%) Top ten global provider of transportation and logistics solutions
  • Mobileye NV (2.88%) Software for camera-based driver assistance systems
  • KAR Auction Services Inc (2.68%) Financial and logistical services for the wholesale used car industry

* Based on percentage of net assets. Holdings can change at any time and should not be considered investment advice.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

View the fact sheet and quarterly report for the Eventide Gilead Fund

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

  • Non-diversified mutual fund investing in healthcare and life sciences
  • Uses bottom-up fundamental research to find companies with the potential to appreciate in value as positive data is released regarding clinical trials and FDA feedback, and market acceptance of products.
  • Under normal market conditions, the Fund will invest at least 80 percent of its net assets in equity and equity-related securities of companies in the healthcare and life sciences sectors.

Healthcare and life sciences companies include those companies that derive or are expected to derive 50% or more of their revenue from healthcare and life science products and services including, but not limited to, biotechnology, pharmaceuticals, diagnostics, life science tools, medical devices, healthcare information technology, healthcare services, synthetic biology, agricultural and environmental management, and pharmaceutical manufacturing products and services. These companies include smaller development-stage companies.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

Dr. Finny Kuruvilla has a unique background in healthcare, statistics, and investing. He holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a master’s degree in Electrical Engineering and Computer Science from MIT, and a bachelor’s degree from Caltech in Chemistry. He completed his residency and fellowship at the Brigham & Women’s Hospital and Children’s Hospital Boston where he cared for adult and pediatric patients suffering from a variety of hematologic, oncologic, and autoimmune disorders. Subsequently, he was a research fellow at MIT where he designed and implemented statistical algorithms involving logistic regression and pseudo-Bayesian expectation maximization. As an avid proponent of values-based investing, Dr. Kuruvilla has developed standards for selecting ethical companies at the outset of the stock selection process.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

As of June 30, 2016:

Portfolio Composition

† Companies valued at greater than $10 billion are Large Cap; those at less than $1 billion are Small Cap. Portfolio Composition is subject to change at any time. Past performance does not assure future results.
‡ Industry Allocation is subject to change at any time. Past performance does not assure future results.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

As of June 30, 2016:

EHLSF-performance

Performance is historic and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. To obtain the most recent month-end performance information and a current prospectus please call the fund, toll free at 1-877-771-EVEN (3836).

Eventide Healthcare & Life Sciences Fund’s Class N expenses: Net Expenses 1.52%.

† These charts compare the Eventide Healthcare & Life Sciences Fund to index fund performance over the previous periods shown, and since inception. Because of ongoing market volatility, Fund performance may be subject to substantial short-term changes. Since Inception returns pertain to Class N and are annualized and assume the inception date of 27 December 2012. Performance will differ for other fund classes, based upon fees and commissions. The S&P 500 is an index created by Standard & Poor’s of American stocks with the largest market capitalization. It is not an investment product. The volatility of the index may be materially different than that of the Fund, and investors should not expect the Fund to achieve the same results as the index.

‡ Returns pertain to Class N.

** The Healthcare Blended Index is composed of equal parts of the S&P 400 Healthcare Index and the S&P 600 Healthcare Index from fund inception on 27 December, 2012. The volatility of the index may be materially different than that of the Fund, and investors should not expect the Fund to achieve the same results as the index.

†† Aggregate total return, not annualized.

‡‡ Annualized since inception returns assume an inception date of 27 December 2012.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

As of June 30, 2016:

Market Risk

** Source: Zephyr StyleADVISOR, with Fund returns supplied to Zephyr by Morningstar, Inc.Standard deviation of return measures the average deviations of a return series from its mean. StyleADVISOR calculates standard deviation as the square root of the squared differences of each monthly return from the mean monthly return over the specified period. Beta is a measure of systematic risk, or the sensitivity of ETNHX to movements in the S&P 500 Index (Index). StyleADVISOR defines Beta as the covariance of ETNHX and Index divided by the variance of the Index. Alpha is the mean of the excess return of ETNHX over beta times the Index. The R-Squared (R2) of ETNHX versus the Index is a measure of how closely related the variance of ETNHX returns and the variance of the Index returns are. StyleADVISOR calculates R2 by squaring the correlation of monthly returns between ETNHX and the Index over the specified period.

†† Annualized since inception market risk details assume inception date of 1 January 2013 and not Fund’s actual inception date of 27 December 2012, as only full month data is included in the market risk calculations.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

As of June 30, 2016:

  • Supernus Pharmaceuticals Inc (3.89%) Pioneering new medicines in neurology and psychiatry
  • Five Prime Therapeutics Inc (3.70%) Screening human proteins to discover and develop novel drugs
  • Collegium Pharmaceutical Inc (3.22%) Abuse-deterrant treatments for chronic pain
  • Loxo Oncology Inc (3.08%) Treating cancer at the genomic level with targeted chemical therapies
  • DBV Technologies SA (2.70%) Patient-friendly therapies for food and pediatric allergy patients
  • Seattle Genetics Inc (2.62%) Antibody-drug combinations to treat lymphoma and other cancers
  • Spark Therapeutics Inc (2.54%) Developing one-time gene therapies for genetic diseases
  • TESARO Inc (2.51%) Drugs to treat cancers and reduce therapeutic side-effects
  • Kite Pharma Inc (2.46%) Clinical-stage therapies that harness patients’ immune systems to fight cancer
  • Celgene Corp (2.46%) Discovery, development and commercialization of life-changing cancer therapies

* Based on percentage of net assets. Holdings can change at any time and should not be considered investment advice.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

View the fact sheet for the Eventide Healthcare & Life Sciences Fund

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

Investment Objective: The Eventide Multi-Asset Income Fund seeks current income while maintaining the potential for capital appreciation. The Fund has significant flexibility to achieve its investment objective by primarily investing in a broad universe of income-producing securities. These securities include debt and equity securities of companies in the U.S. and other markets around the world.

These securities may include but are not limited to common stocks, real estate investment trusts (REITs), business development companies, yieldcos, master limited partnerships (MLPs), preferred stocks, corporate bonds, government agency bonds, certificates of deposit, municipal bonds, inflation-linked bonds, mortgage-backed securities, options, exchange traded notes, exchange traded funds and other investment companies (including mutual funds and closed-end funds). The Fund may invest up to 15% of its net assets in companies whose securities may have legal or contractual restrictions on resale or are otherwise illiquid.

Investment Strategy: Eventide uses a two step process to select securities for the Fund. The investment process begins with a “top down” analysis to select a variety of asset classes that are believed to offer the best opportunity for current income and/or capital appreciation. Factors considered include an assessment of current income opportunities, the potential for income growth, valuation, capital appreciation potential and/or portfolio risk/return attributes. The second step is a fundamental “bottom-up” analysis to evaluate specific securities for inclusion in the portfolio. Eventide favors securities that, in its opinion, are attractively valued, provide attractive current income, provide income appreciation potential, provide capital appreciation potential, and/or help to reduce overall portfolio volatility.

Sub-Adviser: Eventide has retained Boyd Watterson Asset Management, LLC to manage some or all of the Fund’s assets allocated for investment in the intermediate-term bond portion of the portfolio. In selecting securities for investment by the Fund, Boyd Watterson employs a top-down approach to determine how to structure the bond allocation taking in to consideration duration, maturity, and sector allocation. Boyd Watterson then initiates a process of security analysis based on several factors including, but not limited to, economic trends, industry assessments and issuer specific credit fundamentals.

Values-based investing: Eventide aims to analyze each potential investment’s ability to operate with integrity and create value for customers, employees, the environment, and other key stakeholders. While few companies may reach these ideals in every area of their business, these principles articulate the Advisor’s ideal characteristics of good corporate behavior. The Advisor makes no guarantee that fund investments will meet any or all of these characteristics.

Learn more about the Eventide Multi-Asset Income Fund in this presentation.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

Martin Wildy, CFA serves in Eventide’s portfolio management team as the lead portfolio manager for the Eventide Multi-Asset Income Fund. Prior to joining Eventide in 2015, Mr. Wildy was a Senior Portfolio Manager with Aris Wealth Services, a division of AssetMark, Inc. where he worked since 2006. Mr. Wildy served on Aris’s Investment Committee and was responsible for investment decisions that impacted a number of the firm’s investment strategies, including Aris’ Income Builder and values-based portfolios. In his role, Mr. Wildy’s responsibilities included developing capital market assumptions, asset allocation decisions, investment due diligence, and portfolio management. Mr. Wildy holds a bachelor’s degree from the Pennsylvania State University in Finance and has held the Chartered Financial Analyst (CFA) designation since 2003.

David M. Dirk, CFA serves as the Portfolio Manager for some or all of the Fund’s intermediate-term bond portion. Mr. Dirk has been co-Director of Fixed Income for the Fund’s Sub-Advisor, Boyd Watterson, with responsibility of directing all Portfolio Management and Trading activity since 2011. This includes the implementation, execution and evaluation of all strategies across Boyd Watterson’s suite of fixed income products. Mr. Dirk joined Duff & Phelps, predecessor to Boyd Watterson Asset Management, in 1996. David holds a CFA Charter from CFA Institute, an MBA from Case Western Reserve University, and a BA from Baldwin-Wallace College. He is also a member of the CFA Society of Cleveland and CFA Institute.

Eventide’s Portfolio Management Team will offer input. Dr. Finny Kuruvilla, Eventide’s Chief Investment Officer, serves in an oversight capacity for all of the firm’s investment strategies while David Barksdale provides quantitative analysis and tools which will assist in the management of the fund.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

As of June 30, 2016:

Portfolio Composition
‡ Industry Allocation is subject to change at any time. Past performance does not assure future results.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

As of June 30, 2016:

Performance

Performance is historic and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. Investors cannot directly invest in an index and unmanaged index returns do not reflect any fees, expenses or sales charges. To obtain the most recent month-end performance information and a current Eventide Multi-Asset Income Fund prospectus please call the fund, toll free at 1-877-771-EVEN (3836).

Eventide Multi-Asset Income Fund Class N expenses: Net Expenses 1.23%.

† These charts compare the Eventide Multi-Asset Income Fund to index fund performance over the previous periods shown, and since inception. Because of ongoing market volatility, Fund performance may be subject to substantial short-term changes. Since Inception returns pertain to Class N and assume the inception date of 15 July 2015. Performance will differ for other fund classes, based upon fees and commissions. The MSCI World All-Country World Index (Net) captures large and mid cap representation across 23 developed markets and 23 emerging markets. The volatility of the index may be materially different than that of the Fund, and investors should not expect the Fund to achieve the same results as the index.

** The Multi-Asset Income Blend is a proprietary Eventide benchmark based on 60% MSCI All Country World Index (Net), 40% Barcap Aggregate Bond Index at inception, rebalanced monthly. The volatility of the index may be materially different than that of the Fund, and investors should not expect the Fund to achieve the same results as the index.

†† Aggregate total return, not annualized; since inception returns assume an inception date of 15 July 2015

As of June 30, 2016:

Market Risk

** Source: Zephyr StyleADVISOR, with Fund returns supplied to Zephyr by Morningstar, Inc.
Standard deviation of return measures the average deviations of a return series from its mean. StyleADVISOR calculates standard deviation as the square root of the squared differences of each monthly return from the mean monthly return over the specified period. Beta is a measure of systematic risk, or the sensitivity of ETNMX to movements in the S&P 500 Index (Index). StyleADVISOR defines Beta as the covariance of ETNMX and Index divided by the variance of the Index. Alpha is the mean of the excess return of ETNMX over beta times the Index. The R-Squared (R2) of ETNMX versus the Index is a measure of how closely related the variance of ETNMX returns and the variance of the Index returns are. StyleADVISOR calculates R2 by squaring the correlation of monthly returns between ETNMX and the Index over the specified period.

†† Since inception market risk details assume inception date of 1 August 2015 and not Class N’s actual inception date of 15 July 2015, as only full month data is included in the market risk calculations.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

As of June 30, 2016:

  • Hannon Armstrong (2.66%) Real estate investment trust financing energy efficiency and renewable energy
  • Spectra Energy Partners LP (2.50%) Energy infrastructure for transport and storage of natural gas
  • Hercules Technology Growth Capital Inc (2.45%) Venture debt financing, primarily for tech companies
  • Macquarie Infrastructure Corp (2.19%) Aircraft services, liquid storage and marine terminals
  • TSMC (2.09%) Design, manufacturing and packaging of integrated circuits
  • Johnson Controls Inc (2.07%) Automotive supplier, advanced battery technologies, energy efficiency
  • Stone Ridge Reinsurance Risk Premium Interval Fund (1.93%) Catastrophe bonds and reinsurance
  • Munich RE ADR (1.91%) One of the largest reinsurance companies in the world, based in Germany
  • Crown Castle International Corp (1.86%) Infrastructure for broadcasting and mobile telephony
  • Brookfield Renewable Partners LP (1.84%) Wind and hydropower facilities in Europe and the Americas

* Does not include Money Market Funds. Based on percentage of net assets. Holdings can change at any time and should not be considered investment advice.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

View the fact sheet, overview, and presentation for the Eventide Multi-Asset Income Fund.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

Mutual Funds involve risk including the possible loss of principal. Past performance does not guarantee future results.The Funds’ ethical values screening criteria could cause it to under-perform similar funds that do not have such screening criteria. The Funds can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. Because of ongoing market volatility, the Funds performance may be subject to substantial short-term changes.

The Eventide Gilead Fund & Eventide Healthcare & Life Sciences Fund can invest in smaller-sized companies which may experience higher failure rates than larger companies and they normally have a lower trading volume than larger companies. The Funds can also have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The Funds can invest in private companies. Private investments include various risks including but not limited to lack of liquidity, capital commitment risk, and valuation risk. Private companies may not be financially profitable and have uncertain futures, thus subject to additional risks. Investors in the Gilead Fund should be aware that companies in the technology industries have different risks including but not limited to products becoming obsolete, and entrance of competing products.

Investors in the Eventide Multi-Asset Income Fund should be aware that interest rates are at historic lows and may change at any time based on government policy. In general, the price of a fixed income security falls when interest rates rise. A rise in interest rates may result in volatility and increased redemptions, which in turn could result in the fund being forced to liquidate portfolio securities at disadvantageous prices. Longer-term securities may be more sensitive to changes in interest rates. The intermediate-term bond portion of the Fund’s portfolio may represent 0% to 100% of the Fund’s portfolio with an average duration of between two and eight years.

The Eventide Multi-Asset Income Fund may invest in other funds. If other funds are utilized, such underlying funds are subject to investment advisory and other expenses, which will be indirectly paid by the Fund. As a result, your cost of investing in the Fund will be higher than the cost of investing directly in underlying funds and may be higher than other mutual funds that do not invest in underlying funds. The Fund may invest, directly or indirectly, in “junk bonds.” Such securities are speculative investments that carry greater risks than higher quality debt securities. There are unique risks associated with REITs, MLPs, preferred stocks, convertible bonds, BDCs, and yieldcos that are covered in the Fund's prospectus and SAI. The Fund is a new mutual fund and has a limited history of operations for investors to evaluate.

An investor should consider a fund's investment objectives, risks, charges and expenses carefully before investing or sending money. This and other important information can be found in the prospectus, which can be obtained at www.eventidefunds.com or by calling 1-877-771-EVEN (3836). Please read the prospectus carefully before investing. Eventide Mutual Funds are distributed by Northern Lights Distributors, LLC, Member FINRA, which is not affiliated with Eventide Asset Management, LLC.

4309-NLD-4-25-2016